Under the terms of the agreement, AlgoNomics is eligible for research funding and subsequent potential milestone payments from Genmab. The research collaboration focuses on the structural properties of fully human antibody and UniBody molecules.
Ignace Lasters, chief scientific officer of AlgoNomics, said: “Combining our structural perspective with the biological and clinical insights of their discovery and development teams may accelerate the development of Genmab’s UniBody technology.”